A pan-genotypic HCV NS3/4A protease inhibitor
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Voxilaprevir

Item No. 33974

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
N-[[[(1R,2R)-2-[5,5-difluoro-5-(3-hydroxy-6-methoxy-2-quinoxalinyl)pentyl]cyclopropyl]oxy]carbonyl]-3-methyl-L-valyl-(3S,4R)-3-ethyl-4-hydroxy-L-prolyl-1-amino-2-(difluoromethyl)-N-[(1-methylcyclopropyl)sulfonyl]-cyclopropanecarboxamide, cyclic (1R→2R)-ether
CAS Number
1535212-07-7
Synonyms
  • GS-9857
Molecular Formula
C40H52F4N6O9S
Formula Weight
868.9
Purity
≥98%
Formulation (Request formulation change)
A solid
Solubility(Learn about Variance in Solubility)
DMF: 30 mg/mlDMSO: 30 mg/mlEthanol: 1 mg/ml
λmax
217 nm
SMILES
O=C([C@H]([C@H](CC)[C@]([H])(C1)OC2=NC3=CC(OC)=CC=C3N=C2C(F)(CCCC[C@@]4([H])[C@](C4)([H])OC(N[C@H]5C(C)(C)C)=O)F)N1C5=O)N[C@]6([C@@H](C6)C(F)F)C(NS(=O)(C7(CC7)C)=O)=O
InChi Code
InChI=1S/C40H52F4N6O9S/c1-7-22-27-19-50(28(22)32(51)48-39(18-23(39)31(41)42)35(53)49-60(55,56)38(5)14-15-38)34(52)30(37(2,3)4)47-36(54)59-26-16-20(26)10-8-9-13-40(43,44)29-33(58-27)46-25-17-21(57-6)11-12-24(25)45-29/h11-12,17,20,22-23,26-28,30-31H,7-10,13-16,18-19H2,1-6H3,(H,47,54)(H,48,51)(H,49,53)/t20-,22-,23+,26-,27+,28+,30-,39-/m1/s1
InChi Key
MZBLZLWXUBZHSL-FZNJKFJKSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $134

    Add

    5 mg

    $598

    Add

    10 mg

    $1,058

    Add
    Cayman Chemical
    Neutrophil Biology Wall Poster

    Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.

    DOWNLOAD NOW
    Product Description

    Voxilaprevir is a pan-genotypic hepatitis C virus (HCV) non-structural 3/4A (NS3/4A) serine protease inhibitor.1 It inhibits replication of wild-type HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, and 6a (EC50s = 1.9-6.6 nM in replicon assays). Voxilaprevir also inhibits replication of mutant HCV genotypes containing NS3 resistance-associated substitutions (EC50s = 3.1, 2.7, and 4 nM for HCV genotypes 1a Q80K, 1a R155K, and 1b D168E, respectively). Formulations containing voxilaprevir have been used in the treatment of chronic HCV infection.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Taylor, J.G., Zipfel, S., Ramey, K., et al. Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi®. Bioorg. Med. Chem. Lett. 29(16), 2428-2436 (2019).